Maya H Buch
Overview
Explore the profile of Maya H Buch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
4449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shukla R, Wakefield R, Ho P, Tan A, Emery P, Plant D, et al.
Rheumatology (Oxford)
. 2025 Feb;
PMID: 39960885
Objectives: To investigate the association between baseline joint-complex inflammation [power Doppler-detected joint synovitis(PDUS) and/or tenosynovitis(PDTS)] and remission in treatment-naïve, new-onset rheumatoid arthritis (RA) patients and to evaluate concordance and discordance...
2.
Alcacer-Pitarch B, Di Battista M, Redmond A, Keenan A, Di Donato S, Buch M, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39878942
Objectives: Peripheral Sensory Neuropathy (PSN) is an under-recognized feature in systemic sclerosis (SSc). Moreover, SSc foot involvement is frequent but poorly investigated. We aimed to provide a detailed characterization of...
3.
Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, et al.
Ann Rheum Dis
. 2024 Dec;
PMID: 39739386
Background: Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of...
4.
Sebbag E, Lauper K, Molina-Collada J, Aletaha D, Askling J, Gente K, et al.
Ann Rheum Dis
. 2024 Dec;
PMID: 39739385
Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice. Objectives: To...
5.
Dyball S, Shukla R, Madenidou A, Buch M, Bruce I, Parker B
Autoimmunity
. 2024 Nov;
57(1):2433237.
PMID: 39606818
Anti-Ro/SS-A antibodies are prevalent across systemic autoimmune rheumatic diseases (SARDs) and may signify a distinctive phenotype. This study aimed to identify protein biomarkers associated with symptom burden and health-related quality...
6.
Buch M, Aletaha D, Combe B, Tanaka Y, Caporali R, Schulze-Koops H, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39455065
Background: Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic...
7.
Mohammed A, Shukla R, Fisher S, Buch M
Rheumatology (Oxford)
. 2024 Oct;
64(3):1541-1542.
PMID: 39412515
No abstract available.
8.
Buch M, Walker D, Edwards C, Barry J, Akroyd L, Ekoka Omoruyi E, et al.
Rheumatology (Oxford)
. 2024 Sep;
PMID: 39331638
Objectives: Clinical trials restricted to moderately active RA are limited. Filgotinib is approved for treating moderate to severe active RA. This post hoc analysis assessed efficacy and safety of filgotinib...
9.
Denton C, De Lorenzis E, Roblin E, Goldman N, Alcacer-Pitarch B, Blamont E, et al.
Rheumatology (Oxford)
. 2024 Sep;
63(11):2956-2975.
PMID: 39255973
This guideline was developed according to the British Society for Rheumatology Guidelines Protocol by a Guideline Development Group comprising healthcare professionals with expertise in SSc and people with lived experience,...
10.
Denton C, De Lorenzis E, Roblin E, Goldman N, Alcacer-Pitarch B, Blamont E, et al.
Rheumatology (Oxford)
. 2024 Sep;
63(11):2948-2955.
PMID: 39255970
This guideline was developed according to the British Society for Rheumatology Guidelines Protocol by a Guideline Development Group comprising healthcare professionals with expertise in SSc and people with lived experience,...